Somatostatin receptor (SSTR) is overexpressed on the majority of neuroendocrine neoplasms cell surface, and somatostatin receptor subtype 2 (SSTR2) has become an essential target for diagnosis and radionuclide therapy of neuroendocrine neoplasms (10). Here, SSTR2 is linked to neuroendocrine neoplasm.